05

2024

-

12

Announcement of the General Administration of CFDA(20160914) on Issuing Prompt Information on Excessively Duplicated Drugs (2016 No. 153)


4,CFDA20160914) Announcement of the General Administration on Issuing Prompt Information on Over-duplication of Drugs (2016Year No.153No.)

Details: In order to accurately reflect the supply and demand dynamics of my country's pharmaceutical market, scientifically guide pharmaceutical research and development institutions and enterprises to conduct orderly research and development and rational declarations, and avoid low-level duplication and waste of resources, in accordance with the Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices (National Development 〔2015>> 〕44No.) and the Announcement on Several Policies for Drug Registration Review and Approval (Announcement of the State Food and Drug Administration2015Year No.230No.) requirements, the State Food and Drug Administration on2012-2014During the year, the situation of listed drugs was combed, according to the number of enterprises that have been approved.20The number of enterprises in the sales approval number exceeds.20Home is the screening criteria, and a total of them are screened out.282An excessive duplication of varieties (in generic names, the same below) is hereby issued.

Note:Duplicate catalogues contain acyclovir.

Business License